CN103371986A - 漆酚化合物在制备抑制肝脏组织纤维化的药物中的用途 - Google Patents
漆酚化合物在制备抑制肝脏组织纤维化的药物中的用途 Download PDFInfo
- Publication number
- CN103371986A CN103371986A CN2012101116415A CN201210111641A CN103371986A CN 103371986 A CN103371986 A CN 103371986A CN 2012101116415 A CN2012101116415 A CN 2012101116415A CN 201210111641 A CN201210111641 A CN 201210111641A CN 103371986 A CN103371986 A CN 103371986A
- Authority
- CN
- China
- Prior art keywords
- laccol
- body weight
- preparation
- group
- liver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 26
- -1 urushiol compound Chemical class 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title abstract description 17
- 229940079593 drug Drugs 0.000 title abstract description 9
- 230000002401 inhibitory effect Effects 0.000 title abstract description 6
- RMTXUPIIESNLPW-UHFFFAOYSA-N 1,2-dihydroxy-3-(pentadeca-8,11-dienyl)benzene Natural products CCCC=CCC=CCCCCCCCC1=CC=CC(O)=C1O RMTXUPIIESNLPW-UHFFFAOYSA-N 0.000 title abstract 6
- IYROWZYPEIMDDN-UHFFFAOYSA-N 3-n-pentadec-8,11,13-trienyl catechol Natural products CC=CC=CCC=CCCCCCCCC1=CC=CC(O)=C1O IYROWZYPEIMDDN-UHFFFAOYSA-N 0.000 title abstract 6
- DQTMTQZSOJMZSF-UHFFFAOYSA-N urushiol Natural products CCCCCCCCCCCCCCCC1=CC=CC(O)=C1O DQTMTQZSOJMZSF-UHFFFAOYSA-N 0.000 title abstract 6
- 210000005228 liver tissue Anatomy 0.000 title abstract 5
- 239000007924 injection Substances 0.000 claims abstract description 27
- 238000002347 injection Methods 0.000 claims abstract description 27
- 150000003839 salts Chemical class 0.000 claims abstract description 26
- DXRKLUVKXMAMOV-UHFFFAOYSA-N Hydrolaccol Natural products CCCCCCCCCCCCCCCCCC1=CC=CC(O)=C1O DXRKLUVKXMAMOV-UHFFFAOYSA-N 0.000 claims description 80
- 210000004185 liver Anatomy 0.000 claims description 50
- 230000008520 organization Effects 0.000 claims description 22
- 230000003176 fibrotic effect Effects 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 4
- 239000011707 mineral Substances 0.000 claims description 4
- 150000007524 organic acids Chemical class 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 4
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000037396 body weight Effects 0.000 description 37
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 34
- 241000699666 Mus <mouse, genus> Species 0.000 description 25
- 239000013641 positive control Substances 0.000 description 17
- 108010067306 Fibronectins Proteins 0.000 description 16
- 102000016359 Fibronectins Human genes 0.000 description 16
- 102000012422 Collagen Type I Human genes 0.000 description 14
- 108010022452 Collagen Type I Proteins 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 10
- 238000003119 immunoblot Methods 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- 206010016654 Fibrosis Diseases 0.000 description 8
- 230000008021 deposition Effects 0.000 description 8
- 230000004761 fibrosis Effects 0.000 description 8
- 238000011532 immunohistochemical staining Methods 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- 230000008595 infiltration Effects 0.000 description 7
- 238000001764 infiltration Methods 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 239000013642 negative control Substances 0.000 description 7
- 102000008186 Collagen Human genes 0.000 description 6
- 108010035532 Collagen Proteins 0.000 description 6
- 206010019668 Hepatic fibrosis Diseases 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 229920001436 collagen Polymers 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 210000004969 inflammatory cell Anatomy 0.000 description 6
- 239000007928 intraperitoneal injection Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 4
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 231100000518 lethal Toxicity 0.000 description 4
- 230000001665 lethal effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- ODIGIKRIUKFKHP-UHFFFAOYSA-N (n-propan-2-yloxycarbonylanilino) acetate Chemical compound CC(C)OC(=O)N(OC(C)=O)C1=CC=CC=C1 ODIGIKRIUKFKHP-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- KBIWNQVZKHSHTI-UHFFFAOYSA-N 4-n,4-n-dimethylbenzene-1,4-diamine;oxalic acid Chemical compound OC(=O)C(O)=O.CN(C)C1=CC=C(N)C=C1 KBIWNQVZKHSHTI-UHFFFAOYSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 206010019663 Hepatic failure Diseases 0.000 description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Natural products OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 208000007903 liver failure Diseases 0.000 description 2
- 231100000835 liver failure Toxicity 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000001117 sulphuric acid Substances 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 1
- 241000208223 Anacardiaceae Species 0.000 description 1
- 208000006154 Chronic hepatitis C Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241000053227 Themus Species 0.000 description 1
- 241000159241 Toxicodendron Species 0.000 description 1
- 244000044283 Toxicodendron succedaneum Species 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 208000010710 hepatitis C virus infection Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 208000007232 portal hypertension Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210111641.5A CN103371986B (zh) | 2012-04-17 | 2012-04-17 | 漆酚化合物在制备抑制肝脏组织纤维化的药物中的用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210111641.5A CN103371986B (zh) | 2012-04-17 | 2012-04-17 | 漆酚化合物在制备抑制肝脏组织纤维化的药物中的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103371986A true CN103371986A (zh) | 2013-10-30 |
CN103371986B CN103371986B (zh) | 2015-08-05 |
Family
ID=49458237
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210111641.5A Expired - Fee Related CN103371986B (zh) | 2012-04-17 | 2012-04-17 | 漆酚化合物在制备抑制肝脏组织纤维化的药物中的用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103371986B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103610668A (zh) * | 2013-11-04 | 2014-03-05 | 南方医科大学南方医院 | 漆酚化合物用于制备抑制Smad3磷酸化的药物的用途 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101805246A (zh) * | 2010-04-16 | 2010-08-18 | 中国科学院昆明植物研究所 | 漆酚化合物,其药物组合物及其制备方法和应用 |
-
2012
- 2012-04-17 CN CN201210111641.5A patent/CN103371986B/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101805246A (zh) * | 2010-04-16 | 2010-08-18 | 中国科学院昆明植物研究所 | 漆酚化合物,其药物组合物及其制备方法和应用 |
Non-Patent Citations (1)
Title |
---|
陈科全等: "核因子N F-k B 与肝纤维化的关系研究现状", 《国际消化病杂志》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103610668A (zh) * | 2013-11-04 | 2014-03-05 | 南方医科大学南方医院 | 漆酚化合物用于制备抑制Smad3磷酸化的药物的用途 |
US9139502B2 (en) | 2013-11-04 | 2015-09-22 | Southern Hospital, Southern Medical University | Use of an urushiol compound in preparation of pharmaceutical compositions for inhibiting Smad3 phosphorylation |
Also Published As
Publication number | Publication date |
---|---|
CN103371986B (zh) | 2015-08-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wang et al. | Angelica sinensis polysaccharide attenuates CCl4-induced liver fibrosis via the IL-22/STAT3 pathway | |
Wang et al. | Activation of PPARγ is required for hydroxysafflor yellow A of Carthamus tinctorius to attenuate hepatic fibrosis induced by oxidative stress | |
Ghosh et al. | Silymarin-a review on the pharmacodynamics and bioavailability enhancement approaches | |
CA2980173A1 (en) | Antiviral activity from medicinal mushrooms containing phenyl carboxylate/acrylate compounds | |
ES2385069T3 (es) | Agentes profilácticos o de alivio para trastorno nervioso periférico inducido por agente anti-cáncer | |
KR101145248B1 (ko) | 신생혈관형성 억제용 한약 조성물 | |
Albani et al. | In vivo activity of albendazole in combination with thymol against Echinococcus multilocularis | |
TWI598104B (zh) | Use of Antrodia cinnamomea extract to improve side effects of chemotherapy | |
Wang et al. | Protective effect of eburicoic acid of the chicken of the woods mushroom, Laetiporus sulphureus (higher Basidiomycetes), against gastric ulcers in mice | |
KR101793379B1 (ko) | 조각자 가시 추출물을 함유하는 전립선암 전이 억제용 조성물 | |
Jia-Yi et al. | Effect and mechanism of Qishen Yiqi Pills on adriamycin-induced cardiomyopathy in mice | |
CN104069096A (zh) | 具有抗hiv潜伏作用的药物及其用途 | |
CN103371986B (zh) | 漆酚化合物在制备抑制肝脏组织纤维化的药物中的用途 | |
CN103371987B (zh) | 漆酚化合物在制备抑制肾脏组织纤维化的药物中的用途 | |
KR20160074719A (ko) | 촉규근 추출물 또는 창출 추출물을 유효성분으로 함유하는 통증의 예방, 치료 또는 개선용 조성물 | |
US20130171263A1 (en) | Snake Powder Extract For Treatment Of Cancer | |
CN110327466B (zh) | 用于治疗肝纤维化的药物组合物及其应用 | |
CN103830255A (zh) | 芍药苷在制备治疗脑血管疾病的药物中的应用 | |
CN106619619A (zh) | 化合物hubin‑1在制备肝脏炎症性疾病预防和/或治疗药物中的用途 | |
US8206760B2 (en) | Composition for inhibition of transplant rejection containing the cordyceps mycellia extract as an active ingredient | |
WO2017217747A1 (ko) | 부종의 치료, 예방 또는 개선용 조성물 | |
Sun et al. | Bisdemethoxycurcumin, a curcumin derivative, ameliorates adjuvant-induced arthritis by suppressing inflammatory reactions and macrophage migration | |
US7846901B2 (en) | Method for inhibiting or treating intestinal damage caused by radiotherapy or chemotherapy comprising administering substance-P | |
CN103690555B (zh) | 一种治疗乙酰胆碱性荨麻疹的药物组合物 | |
TWI439273B (zh) | 以靈芝酸保護心臟免於壞死或損傷之方法與組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: KUNMING INST. OF PLANTS, CHINESE ACADEMY OF SCIENC Effective date: 20141022 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20141022 Address after: 510000, No. 1023 Sha Sha Road, Baiyun District, Guangdong, Guangzhou Applicant after: SOUTHERN MEDICAL University Applicant after: KUNMING INSTITUTE OF BOTANY, CHINESE ACADEMY OF SCIENCES Address before: 510000, No. 1023 Sha Sha Road, Baiyun District, Guangdong, Guangzhou Applicant before: Southern Medical University |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150805 |
|
CF01 | Termination of patent right due to non-payment of annual fee |